User profiles for "author:A. Amit"

Arianna Maever L Amit

University of the Philippines Manila
Verified email at up.edu.ph
Cited by 11953

Five insights from the global burden of disease study 2019

CJL Murray, C Abbafati, KM Abbas, M Abbasi… - The Lancet, 2020 - thelancet.com
Summary The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019
provides a rules-based synthesis of the available evidence on levels and trends in health …

Curcumin, a traditional spice component, can hold the promise against COVID-19?

VK Soni, A Mehta, YK Ratre, AK Tiwari, A Amit… - European Journal of …, 2020 - Elsevier
The severity of the recent pandemic and the absence of any specific medication impelled the
identification of existing drugs with potential in the treatment of Coronavirus disease-2019 …

[HTML][HTML] Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

T Vos, SS Lim, C Abbafati, KM Abbas, M Abbasi… - The lancet, 2020 - thelancet.com
Background In an era of shifting global agendas and expanded emphasis on non-
communicable diseases and injuries along with communicable diseases, sound evidence …

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

…, EA Rozeman, CU Blank, A Ronai, R Shaoul, A Amit… - Science, 2020 - science.org
Bacteria were first detected in human tumors more than 100 years ago, but the
characterization of the tumor microbiome has remained challenging because of its low …

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …

…, T Neunhöffer, M Pölcher, P Wimberger, A Amit… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …

…, G Sonke, F Joly, A Floquet, H Hirte, A Amit… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …

Three-dimensional structure of an antigen-antibody complex at 2.8 Å resolution

AG Amit, RA Mariuzza, SEV Phillips, RJ Poljak - Science, 1986 - science.org
The 2.8 Å resolution three-dimensional structure of a complex between an antigen
(lysozyme) and the Fab fragment from a monoclonal antibody against lysozyme has been …

[HTML][HTML] Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019

KS Ikuta, LR Swetschinski, GR Aguilar, F Sharara… - The Lancet, 2022 - thelancet.com
Background Reducing the burden of death due to infection is an urgent global public health
priority. Previous studies have estimated the number of deaths associated with drug …

[HTML][HTML] Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a …

H Wang, KM Abbas, M Abbasifard… - The Lancet, 2020 - thelancet.com
Background Accurate and up-to-date assessment of demographic metrics is crucial for
understanding a wide range of social, economic, and public health issues that affect …

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis …

…, A Covens, G Sonke, F Joly, H Hirte, A Amit… - The Lancet …, 2021 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …